Reneo Pharmaceuticals IncNASDAQ RPHM Stock Report

Reneo Pharmaceuticals, Inc. is a clinical-stage company, which engages in the research and development of therapies for rare genetic mitochondrial diseases. The company is headquartered in Irvine, California and currently employs 32 full-time employees. The company went IPO on 2021-04-09. The firm is focused on the developing therapies for patients with rare genetic mitochondrial diseases. The firm is engaged in developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the source of energy for cellular processes. REN001 is a selective peroxisome proliferator-activated receptor delta (PPARd) agonist that has been shown to transcription of genes involved in mitochondrial function and fatty acid oxidation (FAO). The firm is developing REN001 in the three rare genetic diseases that present with myopathy and have unmet medical need: primary mitochondrial myopathies (PMM), long-chain fatty acid oxidation disorders (LC-FAOD), and glycogen storage disease type V (McArdle disease). The firm has completed Phase I b clinical trial in patients with PMM to REN001. The company is conducting open-label Phase I b clinical trials of REN001 with LC-FAOD and with McArdle disease.